Marinus Pharmaceuticals, Inc. (MRNS) earnings
MRNS earnings moved a median of -2.84% by the close. Quarterly and annual MRNS reports and results, each read against the price at its own news timestamp. Back to the MRNS overview →
13 measured MRNS earnings events.
Where these MRNS earnings landedvs 13 measured MRNS earnings reactions
| Middle 50% of MRNS earnings reactions | -8.33% to +0.85% |
|---|---|
| Median reaction (to close) | -2.84% |
| Measured reactions | 13 |
Point-in-time · zero look-ahead
Half of the 13 MRNS earnings events with a measured close landed between -8.33% and +0.85%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q MARINUS PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -5.84% | -10.40% | |
| Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results | Press release | -5.84% | -10.40% | |
| Form 10-Q MARINUS PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.85% | |
| Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results | Press release | +0.00% | +0.85% | |
| Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 | Press release | -1.06% | -1.42% | |
| Form 10-Q MARINUS PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +3.85% | -8.33% | |
| Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | +3.85% | -8.33% | |
| Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 | Press release | +5.00% | +5.00% | |
| Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results | Press release | +2.21% | -29.73% | |
| Form 10-K MARINUS PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -7.21% | +0.22% | |
| Form 10-Q MARINUS PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -1.34% | -2.84% | |
| Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results | Press release | -1.34% | -2.84% | |
| Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023 | Press release | +1.67% | +2.28% |
Keep exploring
More MRNS: analyst actions → · SEC filings → · MRNS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) | 692 | -0.06% | 49% |
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| PTC Therapeutics, Inc. (PTCT) | 686 | +0.01% | 50% |
| Gilead Sciences, Inc. (GILD) | 677 | -0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.